Egetis Therapeutics AB (publ) (EGTX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.166x

Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has a cash flow conversion efficiency ratio of -0.166x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-59.00 Million ≈ $-6.35 Million USD) by net assets (Skr355.10 Million ≈ $38.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Egetis Therapeutics AB (publ) balance sheet independence to measure how much of total assets are equity-financed.

Egetis Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Egetis Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EGTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Egetis Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Soren Acquisition Corp. Class A Ordinary Shares NASDAQ:SORN	-0.002x
Anhui Chaoyue Environmental Protection Technology Co. Ltd. SHE:301049	N/A
ProCap Acquisition Corp Class A Ordinary Shares NASDAQ:PCAP	-0.001x
HomeStreet Inc NASDAQ:HMST	-0.024x
VNV Global AB ST:VNV	0.007x
Exotic Food Public Company Limited BK:XO	0.107x
Zippy Technology Corp TW:2420	0.059x
SAB Biotherapeutics Inc NASDAQ:SABS	-0.111x

Annual Cash Flow Conversion Efficiency for Egetis Therapeutics AB (publ) (2010–2024)

The table below shows the annual cash flow conversion efficiency of Egetis Therapeutics AB (publ) from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Egetis Therapeutics AB (publ) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr492.90 Million ≈ $53.04 Million	Skr-227.90 Million ≈ $-24.53 Million	-0.462x	+9.39%
2023-12-31	Skr545.60 Million ≈ $58.72 Million	Skr-278.40 Million ≈ $-29.96 Million	-0.510x	-48.87%
2022-12-31	Skr506.20 Million ≈ $54.48 Million	Skr-173.50 Million ≈ $-18.67 Million	-0.343x	-38.84%
2021-12-31	Skr527.04 Million ≈ $56.72 Million	Skr-130.11 Million ≈ $-14.00 Million	-0.247x	-15.45%
2020-12-31	Skr629.63 Million ≈ $67.76 Million	Skr-134.64 Million ≈ $-14.49 Million	-0.214x	+16.41%
2019-12-31	Skr244.88 Million ≈ $26.35 Million	Skr-62.64 Million ≈ $-6.74 Million	-0.256x	+30.13%
2018-12-31	Skr219.36 Million ≈ $23.61 Million	Skr-80.31 Million ≈ $-8.64 Million	-0.366x	-28.47%
2017-12-31	Skr303.71 Million ≈ $32.68 Million	Skr-86.55 Million ≈ $-9.31 Million	-0.285x	-207.40%
2016-12-31	Skr389.56 Million ≈ $41.92 Million	Skr-36.12 Million ≈ $-3.89 Million	-0.093x	+91.29%
2015-12-31	Skr48.03 Million ≈ $5.17 Million	Skr-51.15 Million ≈ $-5.50 Million	-1.065x	-133.30%
2014-12-31	Skr90.66 Million ≈ $9.76 Million	Skr-41.38 Million ≈ $-4.45 Million	-0.456x	+23.63%
2013-12-31	Skr46.95 Million ≈ $5.05 Million	Skr-28.07 Million ≈ $-3.02 Million	-0.598x	-0.89%
2012-12-31	Skr53.94 Million ≈ $5.80 Million	Skr-31.96 Million ≈ $-3.44 Million	-0.592x	-260.23%
2011-12-31	Skr87.53 Million ≈ $9.42 Million	Skr-14.40 Million ≈ $-1.55 Million	-0.164x	+57.69%
2010-12-31	Skr6.99 Million ≈ $752.22K	Skr-2.72 Million ≈ $-292.41K	-0.389x	--

About Egetis Therapeutics AB (publ)

ST:EGTX Sweden Biotechnology

Market Cap

$261.74 Million

Skr2.43 Billion SEK

Market Cap Rank

#15424 Global

#252 in Sweden

Share Price

Skr6.11

Change (1 day)

+1.83%

52-Week Range

Skr4.32 - Skr6.77

All Time High

Skr57.90